Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA VI: NORD Wants Reviewers To Be More Accessible

Executive Summary

As rare disease experts become part of orphan drug reviews, stakeholder group says they also should be more accessible to the public.

Advertisement

Related Content

US FDA Planning Another Patient Group To Boost Involvement
US FDA Patient Affairs Office Could Accelerate Involvement With 'Central Entry Point'
You Just Have To Wait: FDA Can't Hurry PDUFA VI Guidances
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
FDA Quietly Consults Patients To Understand Vimizim's Six-Minute Walk Significance
Patient-Focused Drug Development At 10: Where Does It Go From Here?
Group Submits Duchenne Muscular Dystrophy Guidance, Hoping To Direct FDA Policy
FDA’s Patient-Focused Drug Development Meetings Inspire Imitators
Rare Disease Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds

Topics

Advertisement
UsernamePublicRestriction

Register

PS118982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel